Jefferies Global Healthcare Conference in London - SAB BIOTHERAPEUTICS INC
Hi, everyone. Thank you so much for joining us at the Jefferies London Conference. My name is Cha-Cha Yang. I'm a senior associate working with Roger Song, my analyst in the Boston office. We cover Smidcat Biotech. And it is my pleasure today to welcome- Pleasure to be here. So, Sam, maybe we do a high-level introduction for SABbio first. Can you just tell us what you guys have accomplished in the last year and what you're looking forward to in 2027? Yes. So SABBio is a clinical stage biopharmaceutical company. We are in a pivotal study for the treatment of type 1 diabetes. And we have a proprietary drug, which is a human antithymocyte immunoglobulin or thymocyde-targeting plasma-derived IgG. and we are currently in a pivotal study which should be completing enrollment this month. Okay, that's very exciting. And there's been a lot of increasing spotlight on the T1D space over the last few years, and you guys are specifically focused on that. So with a lotof approvals and new innovative data coming out in this space, with your experience at SAB, can you just speak more to how you have seen this disease space evolve, and whether that be from investors, from pharma, patient communities, the excitement in the space that's coming up. Yes. So for many years, a lot of the innovation was around insulin delivery and glucose monitoring, which certainly sort of increased the convenience for the patient. And then there has been a lotof attention and excitement around islet cell transplant, which is really today a last stage therapy for patients that have lost all their ability to make their own insulin and recently over the last couple of years there has been more and more focus on first-line treatment for new patients to preserve their ability make insulin and that's through immunomodulation and our the doctors and the experts and we've complied with the drug companies have come to realize that our first obligation for type 1 diabetes diabetes patients is to preserve their ability to make insulin. Like with any autoimmune disease, when you recognize that a patient is not tolerated to a key organ, our goal is to save that organ. T-Zield was approved, the first immunomodulator, in June of this year, and now there's an approved therapy to preserve the patient's ability to making insulin, which is doing a lot to educate the medical community and get awareness around there, around the importance of preserving insulin production, and we're following close behind with what we believe is a superior product for preservation of the patient's ability to make their own insulin. Yeah, so you mentioned T-Zield, which was an exciting approval, and there are a couple other companies that are making these immunomodulators. So can you speak more to how SAB-142 is different from these approaches? Yes, so T-zield, which is the only approved drug, is a monoclonal antibody targeting T-cells, and it has shown the ability to preserve C-peptide, which is the key marker for a patient's endogenous insulin production. And to date in clinical trials, it has only shown theability to preserve C-PEPTIDE, but it has not shown clinical endpoints such as HbA1c or insulin use. It also requires 12 days of continuous dosing. And our drug, the human IgG, or human antithymosine immunoglobulin, based on the data that we have to date from our own drug and a reference product, is two-day dosing. There's evidence that the drug should reduce HbA1c, a functional or clinical marker, and it's a drug that can be redosed for the life of the patient to continue to provide therapy to maintain insulin production. And so you guys are in phase 2B right now, and you have your top line data coming out in 2027. Can you tell us more about your primary endpoint that you're testing and what the benchmarks for success will look like? And then more specifically, we'd love to learn more about the historical data that drove your powering assumptions, if you could speak more to that. Sure. So in this field of immunomodulation for newly diagnosed patients, the primary endpoint, which is really the measure of your drug doing the job, is C-peptide, and we're looking to preserve C-pectide compared to placebo, and that's the sign of efficacy in a drug. C-peptide is the measure of endogenous insulin production. The key secondary endpoints are HbA1c, which shows that with that benefit of preserved C-peptide, the patient has better glycemic control, which is meaningful to the patient and the doctor. And sorry, can you just do the part B and C? Oh yeah, really just about benchmarks and also more so about like what are your historical... So for benchmarks, TZL, the approved drug, has shown preservation of C-peptide but has not shown efficacy or hitting any secondary endpoints. So they have not reduced HbA1c or they haven't shown it. They haven't reduced insulin use. They haven' t reduced or they ha' n't improved glycemic control as measured by time in range. And we believe we have the ability to do that based on these historical benchmarks. so an important foundation for our program is a drug with the same mechanism of action which is called thymoglobulin it's a commercial product for organ transplant it's sold by sanofi and it has been shown to both preserve c-peptide and reduce hb1c in the same patient population in two different clinical trials randomized double-blinded clinical trials one is called TN-19, and one is called MELT. Now, that drug, thymoglobulin, is made in rabbits, and it is a rabbit-derived antithymocyte globulin. And because it is rabbit protein, or rabbit IgG, it is highly immunogenic, which leads to serum sickness in AE, which is really undesirable, and it can't be redosed. So it's a one and done. You can't get that drug twice, and this is a chronic disease. Our drug is the same type of drug, but it's fully human, and we've already shown in phase one it is not immunogenic, and it does not cause serum sickness. So we believe we can rely on the efficacy as seen with thymoglobulin, and we have already shown that we have the advantages needed for a good target product profile, which is redosability and no serum sickness, Now, our clinical trial design was modeled after one of these studies, which was called TN19, in which we had all of the data given to us with permission and were able to use the variability and the patient inclusion and exclusion criteria to design the study. So we've designed effectively the same study and powered accordingly as the thymoglobulin study, which showed both preservation of C-peptide as well as HbA1c, giving us high confidence in our likelihood of success. That's really exciting. So we talked a little bit about the convenience factor we talked about, the efficacy you're looking at. Can you just tell us more about the safety data that you're expecting to see, and are there any AEs that we should be on the lookout for? so um we did a phase one we presented safety data and the majority of aes are infusion related and resolve a day after the infusion so they are um reversible resolvable and basically manageable by the doctor the most common ae is headaches and if those headaches are accompanied by a fever, they call that grade one CRS. So the presence of a fever or a flu-like symptom. And that is something that is common. It is on target, but it's easily managed with steroids and NSAIDs, and it resolves within a day. Okay, that is great to know. And then, you know, SAVEGUARD is a phase 2b study. So can you just talk us through the regulatory path and what you expect the conversations to be with the regulators after your top-line release next year? Yes, so we call it a Phase 2B because it has some dose ranging. It has a higher dose and a lower dose, both active, and for that reason, to be technically accurate, we call it a phase 2B. At the same time, it is a pivotal study. We have agreement with FDA that it is pivotal and can be used for registration. So it's like a phase 3. in terms of the results from this trial of positive are sufficient to file a BLA and market the drug. And so that is based on primarily your C-peptide data, is that correct? Not necessarily based on your HbA1c, or can you clarify that? Yeah, that's a good question. So T-Zield was approved on one study called PROTECT in which they showed C-peptide preservation but did not show any clinical benefit, meaning they didn't show any other secondary endpoints. And that, it's an accelerated approval. They still have an obligation to show secondary or clinical endpoints, but it is a precedent with FDA that C-peptide is sufficient for an accelerated removal. So in the event, which we're not planning for, that we only hit on C-pectide, we would be eligible for an isolated approval based on the thymoglobulin data and our powering and our design of the study we also expect to hit hba1c and hopefully other secondaries which would be a full approval i see and so beyond hba 1c what other functional data do you think you might be able to present next year well in terms of when we present top line data the only thing i know we're going to do now is peptide in HbA1c, but we are also looking at insulin use, the frequency of hypoglycemic events, which if you, that has a big impact on the patient's life. It's very disruptive, and if you can reduce that, that's a very meaningful clinical endpoint. For sure. As well as time and range, HbА1c has been around for a while and is one way to measure glycemic control. Today, almost all patients use continuous glucose monitoring, and every patient in our clinical trial is required to use continuous glucose monitoring so we can measure the amount of time they spend in a normal range, which is also a very precise indicator of glycemic control. I see. And so the potential to file for BLA for accelerated approval just based on C-peptide, let's say in the event that you don't hit on HbA1c, which you said you don' t expect, but in case that does happen, what is the next step for a full approval? Well, the next step would be using the safeguard data, seeing what the trends are or what the delta is in those other endpoints. And with all that information, you can very confidently design a trial to address whatever the shortcomings are, which is most likely power. And then you have an obligation. I like to remind people that, as compared to Sanofi, we're a pre-commercial company, and with an accelerated approval, even though there's an obligation to do another study, the difference between pre-commerce and commercial with revenues is a massive value inflection point, whether it's accelerated or full. Yeah, that makes a lot of sense. And so in addition to Safeguard, you guys are also entering in the Phase 3 Investigator Study. So can you tell us more about that study, about the design, about the goals, and about potentially the primary endpoints that we're looking at there? Yes. So that is called the Prize Study. It is a Phase 3 study, and it was a protocol presented, or investigators, which include Mike Haller at the University of Florida, and chantal matthew at leuven in belgium we're very interested along with the rest of the t1d community with treating patients as far along as possible and the prize study is looking at patients up to two years from diagnosis for context t zealt is approved in patients within eight weeks of diagnosis giving a very tight timetable and window for treatment the safeguard study is within the first 100 days of diagnosis. And all the other clinical research in this sphere of newly diagnosed patients has a very narrow window for treatment and for studying. And so the philanthropy community, the patient community, the KOL community, very concerned about excluding all these patients based on what may be arbitrary, which is time from diagnosis. And that's where our Phase III, the prize study, comes in, and that's why it's funded by Breakthrough, is because of tremendous interest in the academic community. And the prize study is a sister study to Safeguard. It's a phase three, and two cohorts are added. One is what we call cohort two, which is from 100 days to 365 days, and one is cohort three is from 365 days to two years, and that will be compared to cohort one, a synthetic cohort, which is in that first 100 days, which comes from Safegard. But other than that time from diagnosis, the protocol is identical. And so the endpoints are the same, C-peptide preservation, HbA1c as secondary along with those others, insulin use and time and range. And can you remind us what the timelines for data release are on that? so we have less insight into that because that is a study where breakthrough t1d and these academic investigators are running the study and so we don't have as much control over the time it takes to enroll the trial but what I can tell you is that the first patient should be enrolled this quarter and 72 new patients are needed. And it's enrolling at seven sites. So really we, because we are one step removed, we're kind of arm's length, we'll look at how they do the first quarter and, you know, update everyone sort of quarter by quarter to figure out their pace and then be able to kind of estimate when the trial should be done. Okay, sure. Makes sense. And with the data that's generated from this phase three, how do you expect that to go into regulatory conversations, if at all, for SAB 142, whether that be for potential accelerator approval or full approval? So firstly, the safeguard study is our pivotal study, which we can get the drug approved on. The prize study is extra cohorts that aren't included in safeguard. And so it's kind of a win-win. If it doesn't work, it really doesn't impact our study. Even T-Zield is only the first eight weeks, and we're the first 100 days. So we already have a bigger window, can have more market penetration. But if PRISE is successful, if the thesis is correct that time from diagnosis is arbitrary and the drug will work regardless of time from analysis, then we expect to be able to expand the label to include patients up to two years. And I would think, I don't know, but I would thing that if cohort two and three both work, you could make a solid case that time is not relevant and really make the only criteria for treatment C-peptide. So the results being positive would just expand the market opportunity and make patient access easier because patients wouldn't have this clock that expires for getting treatment. Yeah, for sure. And the patient journey is tough the first 100 days or so, so to be able to expand that to give access to more patients would be really exciting. And do you think that would require you to run an additional trial with the longer diagnosis time, or do you think this data from PRISE would be sufficient? PRISE is the study. It's designated by FDA as a phase three. It's powered. Okay, sounds great. And I know you've been talking about T-Zield for this presentation, so we'd love to talk more about that. And we know T- Zield has been recently approved for stage three T1D. So my question really is about how has this shifted the competitive landscape for SAB 142, and how has that shifted the conversations within the T1D space more generally? Yeah, so we've really been following T-Zield with full knowledge of their program and their data from the beginning. And, I mean, we owe a lot to them because they established a regulatory path. What it does is it gets doctors used to prescribing. It educates the health care provider community and diabetes educator community about the importance of C-peptide. And it's really a paradigm shift in how T1D patients are treated. Prior to T-Zield, there was no prescription. There was no treatment for treating the actual disease or disease-modifying therapy. The patients and the doctors simply got into how to measure glucose and how to treat with insulin. So now with T-Zeal, doctors are getting used to writing a prescription and getting a patient infused. Now, we believe we will have a strong second-comer advantage because our differentiation and our competitive advantages are stark. If we just start with the baseline, T-Zield requires 12 days of continuous infusion, which is a very high burden to put on the patients and the doctors, figuring out 12 days if continuous infution, whereas we're two days. Two days versus 12 days is enough on its own. We hope to have superior efficacy with the secondary endpoints, and we have redosability so we can offer the patient the promise of continuous dosing and continuous preservation of their beta cells as opposed to just temporary because T-Zield cannot redose. So we think they're doing a lot of heavy lifting, a lot OF good medical education, and we'll have a strong second-comer advantage. Yeah, and do you have any insights into what the sales uptake is like for stage 3 T1D? Because historically, T-Zield hasn't done particularly well in stage two. So any insight into this new indication expansion? Well, it's an interesting question because I think the idea that T-zield didn't do well in stage two was simply from confusion in the market. So the stage two market and stage two is patients who are asymptomatic that have the presence of autoantibodies for their pancreas. The only way a patient and their family would find out if they were positive for autoantibodies is if they went out of their way, went to an academic institution, and asked to be tested. And so it was kind of like a niche product. And the stage three market is ten times the size of the stage two market. So I think for those who really modeled and forecast that stage two indication, they did quite well. I think they beat expectations. And what people in the market after a $3 billion acquisition, Sanofi paid $3 billion for that drug, had different ideas of what their sales should be when that sales price was probably more built around assuming a Stage 3 approval. So in Stage 2, I think the last quarter that it kind of plateaued was about $25 million, and with the first full quarter in Stage 3, it's like $47 million. I'm not giving exact numbers, approximate, but that's a solid first quarter for a biologic and a new indication where doctors are not used to prescribing. So we were very encouraged by that, despite the 12-day dosing, which we know they're getting a lot of no's because of that very difficult dosing. So considering first quarter, difficult target product profile, I think it's encouraging. Yeah. Enormous commercial opportunity potential here. Yeah. And so we're really reaching the end of our fireside chat. Is there anything that we haven't covered that you'd like to share with the audience today? Well, I think that T1D has largely been underappreciated because drug companies had insulin franchises, and drug companies without insulin franchizes didn't consider themselves type 1 diabetes companies. And what TZL did, and it's very new, it just got approved, is taught everyone that type 1 diabetes is a major unmet need in autoimmunity and should be considered as an autoimmune drug where our goal is to save the organ and so it's kind of an underappreciated space it's a large unmet medical need with really a large totally total addressable market perhaps 20 billion dollar total address able market so it really early days for t1d I think the interest is growing I think we have the most exciting product next in line. And that will really make a big difference in how people think about T1D. And for the patients and the families and the caregivers, we are going to transform what it means to have T1B. Completely agree. And, you know, we haven't really had anything since the discovery of insulin since, you Know, TZL in 1921. So, you Now, patients have been on insulin for over 100 years with really no other therapeutic. So this is an exciting space and excited for SAB in the coming year. Thank you so much. Thank You. Thanks for your time. Thank you.
- Company
- SAB BIOTHERAPEUTICS INC
- Keywords
- SAB BIOTHERAPEUTICS INC